SCHEMBL17181780

SCHEMBL17181780

COc1ccc(OBOc2ccc(OC)c(N)c2)cc1N

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.68
MEN1 O00255 2/20 0.68
MAPT P10636 2/20 0.68
THRB P10828 2/20 0.68
KMT2A Q03164 2/20 0.68
CYP3A4 P08684 3/20 0.53
GAA P10253 2/20 0.50
L3MBTL1 Q9Y468 3/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
TDP1 Q9NUW8 4/20 0.44
APP P05067 1/20 0.44
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
ADRA2B P18089 1/20 0.43
PTGS1 P23219 1/20 0.43
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17181776 0.84 ALDH1A1 (0.68) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL92071 0.83 ALDH1A1 (0.95) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL23115 0.81 CA2 (0.67) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL28683526 0.81 ALDH1A1 (0.91) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL15938210 0.81 ALDH1A1 (0.76) ALDH1A1MEN1MAPTTHRBKMT2A
Hydrochloric Acid SCHEMBL2585553 0.81 ALDH1A1 (1.00) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL23744 0.78 CA12 (0.45) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL177471 0.76 CA12 (0.43) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL23218 0.76 RAB9A (0.46) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL1124557 0.75 ALDH1A1 (0.48) ALDH1A1MEN1MAPTTHRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2925319-B1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIV ROCHESTER (US) 2019-01-09 EP disclosed
EP-3037421-A1 MLK INHIBITORS AND METHODS OF USE University Of Rochester (US) 2016-06-29 EP disclosed
EP-2379561-B1 MLK INHIBITORS AND METHODS OF USE UNIV ROCHESTER (US) 2015-11-04 EP disclosed
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES MLKL, MARCKS, MAP3K4 ALDH1A1 4296/4885MEN1 4220/4885MAPT 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.